Celgene Publishes a Poster from A Pharmacokinetic Study Performed at West Coast Clinical Trials
Dallas, Texas, March 3rd, 2011
At the 112th annual meeting of American Society for Clinical Pharmacology and Therapeutics (ASCPT) in Dallas, Texas, Celgene presented the poster titled “Safety, Tolerability, and Pharmacokinetics of Ascending Single Oral Doses of CC-930, A Novel JNK Inhibitor, in Healthy Subjects.” Dr. Apinya Vutikullird was the principal investigator for the study conducted at West Coast Clinical Trials.
About West Coast Clinical Trials
WCCT is a privately owned independent Phase I-IV CRO, conveniently located near 3 major airports in Southern California. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. WCCT’s location and access to an ethnically diverse population allows for a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 40,000 square feet, a well-trained and experienced staff, and advanced technological procedures, WCCT brings the highest quality to the pharmaceutical and biotechnology industries.
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. Celgene seeks to deliver truly innovative and life-changing drugs for their patients. Their mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.